Treadwell Announces Ocifisertib, a First-in-Class PLK4 Inhibitor, has Received Orphan Designation fr

With a Focus on Potential Pivotal Studies in 2025, Treadwell has Strengthened its Leadership Team by Appointing Brenda Marczi, PharmD, MBA as SVP and Head of Regulatory AffairsTORONTO & SAN FRANCISCO--(BUSINESS WIRE)--Treadwell Therapeutics, a privately held clinical-stage biotechnology company pioneering and advanc...

Related Keywords

United Kingdom ,Toronto ,Ontario ,Canada ,Brenda Marczi ,Roger Sidhu ,University Of Pennsylvania ,Rutgers University ,Regulatory Affairs At Tracon Pharmaceuticals Inc ,University Of Maryland ,Drug Administration ,Leadership Team ,Head Of Regulatory Affairs ,Regulatory Affairs At Treadwell ,Potential Pivotal Studies ,Appointing Brenda Marczi ,Treadwell Therapeutics ,Drug Act ,Senior Vice President ,Regulatory Affairs ,Tracon Pharmaceuticals ,Pharmaceutical Sciences ,